The Joint (US:JYNT) GlobeNewswire News Room·2025-08-12 08:00Core Viewpoint - Rakovina Therapeutics and NanoPalm Ltd. have signed a non-binding Letter of Intent to form a joint venture aimed at co-developing novel small-molecule oncology therapeutics, starting with the drug kt3283, utilizing NanoPalm's advanced pLNP delivery technology [1][6]. Company Overview - Rakovina Therapeutics is a biopharmaceutical company focused on cancer therapies, leveraging AI-powered drug discovery technologies, including the proprietary Deep Docking™ platform [13]. - NanoPalm Ltd. is a Saudi-based biotechnology company specializing in AI-designed pLNP delivery systems for gene and drug therapies, originally developed for gene therapy applications [11][12]. Joint Venture Details - The joint venture will focus on advancing kt3283, a dual-function PARP-HDAC inhibitor, through late preclinical development and early clinical studies, while also evaluating additional AI-derived drug candidates [6][9]. - The collaboration will be based in Saudi Arabia, with a global development and commercialization mandate, marking the first pLNP-oncology-focused biotech initiative in the region [9][16]. Technology and Innovation - Rakovina's AI-enabled drug discovery engine can rapidly screen billions of molecules against cancer targets, while NanoPalm's pLNP technology enhances therapeutic delivery precision and efficacy [2][4]. - kt3283 has shown strong preclinical activity in Ewing sarcoma, breast, and ovarian cancer models, demonstrating enhanced cytotoxicity compared to existing PARP and HDAC inhibitors [3][4]. Strategic Goals - The partnership aims to create a robust pipeline of novel therapeutics, with plans for global licensing and commercialization opportunities as the development pipeline matures [6][9]. - The joint venture will adhere to international regulatory standards, including those of the FDA, SFDA, and EMA, ensuring compliance and facilitating market entry [9][10].